TCTMD

Philips Response to ResMed Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea and Chronic Heart Failure

On May 15, 2015, Respironics, Inc., a Philips business, provided the following response to ResMed's Update on Phase IV SERVE-HF Study of Adaptive Servo-Ventilation (ASV) Therapy in Central Sleep Apnea ...
The American Journal of Managed Care

Dr Michael Arzt Analyzes ASV Therapy, Targets Treatment-Emergent Central Sleep Apnea With CVC

Michael Arzt, MD, investigated the use of ASV therapy in patients with TE-CSA and cardiovascular disease, finding it effective in reducing sleepiness and improving quality of life. It may be more ...
MedPage Today

No Improved Outcomes for HF Patients With Sleep Apnea Using ASV Breathing Devices

Breathing machines with adaptive servo-ventilation (ASV) did not improve survival or other clinical outcomes in patients with heart failure (HF) and reduced ejection fraction and sleep-disordered ...
Reuters

Respironics says FDA gives marketing approval to BiPAP autoSV

March 7 (Reuters) - Respironics Inc. said U.S. regulators granted approval to market its ventilatory support device, BiPAP autoSV, for sleep-disordered breathing patients. The company said the device ...